Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Vaccines news

Show

From To
Will an HIV vaccine that protected two-thirds of monkeys do the same for humans?

The Lancet last Friday published the 52-week results of APPROACH, an HIV vaccine whose 28-week results, reported by aidsmap.com last year, were sufficiently impressive for it to

Published
13 July 2018
By
Gus Cairns
Novel HIV vaccine candidate is safe and induces immune response in healthy adults and monkeys

New research published in The Lancet shows that an experimental HIV-1 vaccine regimen is well-tolerated and generated comparable and robust immune responses against HIV in healthy adults and rhesus monkeys. Moreover, the vaccine candidate protected against infection with an HIV-like virus in monkeys.

Published
09 July 2018
From
Eurekalert Inf Dis
Abivax releases positive top line data from ABX464-005 phase 2a study in HIV infection

“These findings show, for the first time, that ABX464 has the ability to reduce HIV DNA in both blood and rectal tissue reservoirs,” said Dr Jean-Marc Steens, Chief Medical Officer at ABIVAX. “The longer 12 week duration of treatment with ABX464 was safe and generally well tolerated and supports extended dosing.”

Published
04 July 2018
From
Abivax press release
HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains

NIH study results represent major advance for structure-based HIV vaccine design.

Published
05 June 2018
From
National Institutes of Health (press release)
Healthy competition intensifies 30-year quest for HIV vaccine

By funding two similar projects at once, the EU aims to inspire a sense of friendly competition between them. But the programmes share researchers and conduct complementary work, careful not to duplicate their efforts. Both Prof. Shattock and Prof. Pantaleo say that either European team would be happy if the other found a vaccine that worked.

Published
21 May 2018
From
Horizon magazine
Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial

Inovio Pharmaceuticals, Inc. today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study. Inovio previously reported that PENNVAX-GP elicited the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine.

Published
16 May 2018
From
Inovio press release
Genetically Altered Broadly Neutralizing Antibodies Protect Monkeys from HIV-Like Virus

Single infusions of each modified bNAb protected two groups of six monkeys each against weekly exposures to simian-human immunodeficiency virus (SHIV) for up to 37 weeks, compared with a median of 3 weeks in 12 monkeys receiving no antibody.

Published
16 April 2018
From
NIAID press release
Zambia, South Africa prevention study finds those with herpes virus facing six times HIV risk

Communities’ HIV prevalence could be predicted “almost exactly” from prevalence of herpes virus, researchers find.

Published
14 April 2018
From
Science Speaks
Call to extend HPV vaccine to boys as cancer rates soar

NHS England urged to act after new figures reveal rising head and neck tumours in men: Health officials will soon come under increasing pressure to extend vaccination against the cancer-causing human papilloma virus to young men. Doctors say new figures, to be released in a few weeks, will show that rates of head and neck cancers in men are now rising so quickly that it is imperative the policy is reversed. “To be blunt, the case for giving the vaccine to boys as well as girls is now unequivocal as far as I am concerned,” said Professor Mark Lawler, of Queen’s University Belfast. “We have a chance to eradicate both these conditions – cervical as well as neck and head cancers – and we should not be hesitating.”

Published
01 April 2018
From
The Guardian
Better ways to combat HIV than seeking a vaccine

Are human-vaccine trials the best use of resources? Based on the current reality, HIV treatment and prevention strategies that have been proven to work would be a much better use of the millions of dollars being spent on the large-scale vaccine clinical trials.

Published
22 March 2018
From
Business Day
← First12345...38Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.